Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,248 across all filing types
Latest filing 2019-08-05 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Please find enclosed herewith the copy of the newspaper advertisement of notice of Board Meeting of the Company will be held on Monday, August 12, 2019 at the registered office of the Company, ....
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled for August 12, 2019, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2019. It includes a newspaper advertisement of the notice and mentions regulatory compliance with SEBI listing obligations and insider trading regulations. The document does not contain the financial results themselves but announces the meeting where these results will be approved. The length is 4649 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory announcement about the board meeting and financial results approval, not the financial report itself.
2019-08-05 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is extremely short (326 characters) and consists only of an address to stock exchange listing departments with no substantive content or financial data. It appears to be a brief communication or notice rather than a full report or detailed announcement. There is no indication of financial results, management changes, voting results, or other specific report content. Given the brevity and format, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other specific categories.
2019-08-01 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2019 ,inter alia, to consider and approve the Un-audited Standalone ....
Regulatory Filings Classification · 95% confidence The document is a notification titled 'Intimation of Board Meeting' dated August 1, 2019. It informs about an upcoming Board Meeting scheduled for August 12, 2019, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2019. The document references regulatory compliance under SEBI regulations and mentions the closure of the trading window for insiders. The content is an announcement of a board meeting and the agenda to approve quarterly financial results, but it does not contain the financial results themselves or detailed financial data. The document length is 3390 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement about a board meeting and upcoming financial results, not the financial report itself or a detailed management discussion.
2019-08-01 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 95% confidence The document is an intimation regarding the loss of share certificates and the issuance of duplicate share certificates under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a notification to the stock exchange or regulatory body about a shareholder's request for duplicate share certificates due to loss of original certificates. The content is administrative and regulatory in nature, related to share certificate management, and does not contain financial statements, management discussion, or other report content. It is not a financial report, earnings release, or management report. It is also not a report publication announcement or certification. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-07-25 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (376 characters) and contains no meaningful content or identifiable keywords related to any specific financial report or announcement. It appears to be mostly formatting or placeholder text with no substantive information. Given the lack of content and the very short length, this document does not represent a full report or detailed announcement. According to the rules, such documents are best classified as Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2019-07-16 English
Pursuant to the SEBI Circular No. SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated 6th November, 2018, we would like to inform you that the Company has received through its Registrar & Share Transfer ....
Regulatory Filings Classification · 95% confidence The document is an official communication from Bliss GVS Pharma Ltd. dated July 16, 2019, regarding the proposed transfer of shares pursuant to a SEBI circular dated November 6, 2018. It includes details about requests for transfer of physical shares, a notice published in newspapers, and instructions for objections within 30 days. The content is focused on regulatory compliance and shareholder notification about share transfers, not financial results, management changes, or other report types. The document is not a financial report, earnings release, or management discussion. It is a regulatory announcement related to share transfer procedures as per SEBI guidelines. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-07-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.